Diabetes

La diabetes es una enfermedad metabólica producida por la elevación anormal de azúcar en la sangre. Una persona es diabética cuando sus valores basales de glucosa en sangre son superiores a 126 mg/dl en dos análisis consecutivos o cuando presentan un valor de hemoglobina unida a glucosa (hemoglobina glucosilada) por encima del 6,5%A diabetes é unha enfermidade metabólica producida pola elevación anormal de azucre no sangue. Unha persoa é diabética cando os seus valores basales de glicosa en sangue son superiores a 126 mg/dl en dúas análise consecutiva ou cando presentan un valor de hemoglobina unida a glicosa (hemoglobina glucosilada) por encima do 6,5

Cost Analysis of FreeStyle Libre ® 2 System in Type 2 Diabetes Mellitus Population

FreeStyle Libre ® 2 system is a sensor-based flash-monitoring system that measures interstitial fluid glucose. The study aimed to compare cost of FreeStyle Libre 2 system and self-monitoring of blood glucose (SMBG) in the type 2 diabetes mellitus (T2DM) population from the Spanish Health System perspective. On the basis of data collected from a literature review, the cost of glucose monitoring was modelled for patients with T2DM on a basal-bolus insulin regimen. The cost estimate included annual consumption for glucose monitoring (strips, lancets and sensors) and severe hypoglycaemic events (SHE) management. A published rate of SHE (2.5 episodes/patient-year) was considered. A reduction of SHE (− 48.8%) associated with FreeStyle Libre 2 system, derived from the REPLACE trial, was applied. Hospital attendance for 20.5% of SHEs (with subsequent hospitalization in 16.0%) was applied. Consumption of strips and lancets was set at 6/day for SMBG (derived from national monitoring recommendations), and 0.2/day for FreeStyle Libre 2 system users, with 26 FreeStyle Libre 2 sensors/year. Unitary costs (€, year 2020 excluding VAT) were derived from literature (€0.28/strip; €0.09/lancet; €3.09/daily FM sensor; €3804/hospitalized SHE; €1794/hospital-attended non-admitted SHE; €389/community-attended SHE). Costs were €2700 and €2120/year/patient using SMBG or FreeStyle Libre 2 system, respectively. For 1000 patients with T2DM using basal-bolus insulin, 1220 SHEs/year (with 48 hospitalizations) could be prevented and FreeSytle Libre 2 system could generate cost savings of up to €580,953/year versus SMBG (− 21.5%). FreeStyle Libre 2 system is a potential cost-saving strategy in patients with T2DM in Spain on a basal-bolus insulin regimen